6th ESH Translational Research Conference: Lymphoid Malignancies Webcast

6th ESH Translational Research Conference: Lymphoid Malignancies Webcast
 IMAGE   11/2021

The ESH 2021 satellite symposium features expert discussions on the inhibition of Bruton’s tyrosine kinase (BTK) as a key approach to manage and treat indolent B-cell lymphomas. The symposium was chaired by Professor Véronique Leblond (Head of the Department of Hematology at Pitié Salpêtrière Hospital, Paris, France) and offers insights into targeting of the TLR pathway with BTK inhibitors in Waldenström’s macroglobulinemia (WM), current and emerging treatment options for WM patients, and the impact of COVID-19 disease and vaccination on the management of WM.

Professor Véronique Leblond introduces the symposium and speakers, and outlines the session objectives and agenda.

Welcome, introductions and learning objectives

Professor Steven Treon (Director of the Bing Center for Waldenström’s macroglobulinemia, Senior Physician at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, Boston, USA discusses targeting of the TLR pathway with BTK inhibitors in Waldenström’s macroglobulinemia.

Professor Marie José Kersten (Head of the Department of Hematology Academic Medical Center in Amsterdam, Netherlands) explores the selection of treatment for Waldenström’s macroglobulinemia patients within the current treatment paradigm and the evolving treatment landscape.

Professor Christian Buske (Medical Director at the Comprehensive Cancer Center and Institute of Experimental Cancer Research in Ulm, Germany) provides insights into the impact of COVID-19 disease and vaccination on the management of Waldenström’s macroglobulinemia patients.

The presentations are followed by a panel discussion and a Q&A session moderated by Professor Véronique Leblond.

Discussion and Q&A

Audience Q&A

 

Rating

Rate this resource